Bone morphogenic protein (BMP-7) & CKD

Hi y’all,

I wasn’t familiar with this, but got an email with some interesting links that I wanted to share with you, starting with this (posted here:

Public release date: 26-Jun-2003

Contact: Bonnie Prescott
Beth Israel Deaconess Medical Center
New study demonstrates bone protein can reverse kidney failure

BOSTON – A new study led by investigators at Beth Israel Deaconess Medical Center (BIDMC) has shown that a protein used to heal fractured bones is effective in repairing and reversing chronic renal disease, a leading cause of morbidity and mortality throughout the U.S.

These findings, which are reported in the July 2003 issue of Nature Medicine, could help lead to the development of a therapeutic alternative for the nearly 300,000 kidney disease patients who are currently undergoing dialysis.

“Dialysis is not really a treatment, it’s just a means of survival until an opportunity for a transplant opens up,” notes the study’s senior author Raghu Kalluri, Ph.D., director of the Center for Matrix Biology at BIDMC and Associate Professor of Medicine at Harvard Medical School. “This is a very tedious way of living life,” he adds, explaining that the process of mechanically filtering blood through a machine to remove waste products must be performed several times a week for a period of three to four hours per visit, posing risks of infection and other side effects. Furthermore, the procedure is extremely costly.

The kidneys function as a filtration system, keeping the body’s blood supply healthy by removing excess fluids and wastes, as well as by producing hormones. When kidneys “fail” – as can result from complications associated with diabetes, lupus or several other diseases – harmful wastes accumulate in the bloodstream, excess fluids build up in the body, and red blood cell production is impeded. Once chronic kidney disease develops, it cannot be reversed or repaired; when the organs cease to function, patients have no alternative but to undergo dialysis while awaiting a kidney transplant.

This new study looked at the role of a molecule called bone morphogenic protein (BMP)- 7 which, in its recombinant form, has been approved by the U.S. Food and Drug Administration for the treatment of bone fractures. Earlier studies had revealed that BMP-7 is highly expressed in the kidneys of healthy individuals. “We wanted to learn if this protein was somehow offering protection against kidney injury,” explains Kalluri.

The investigators used mouse models of chronic renal injury, characterized by the presence of scar tissue known as renal fibrosis; once kidney disease was well-established in the animals, they administered human recombinant BMP-7.

“We found that in the kidneys, BMP-7 reverses a process known as epithelial-to-mesenchymal transition, which generates scar-causing cells known as fibroblasts,” says Kalluri, explaining that BMP-7 first reduces the number of the fibroblast cells, and then replaces the damaged areas of the kidney tubules with healthy epithelial cells. “In effect,” he adds, “BMP-7 is decreasing the bad cells [in this context, fibroblasts] and converting them into good cells [in this context, epithelial cells].”

Although therapies exist to slow progression of kidney disease, once it has developed it becomes intractable, eventually leaving patients no alternative but to undergo dialysis. “The possibility of creating a cost-effective drug that would actually reverse renal injury could significantly reduce the need for dialysis and significantly improve the quality of life for these patients,” says Kalluri.

Study co-authors include BIDMC investigators Michael Zeisberg, M.D., Jun-ichi Hanai, M.D., Hikaru Sugimoto, M.D., Ph.D., Tadanori Mammoto, Ph.D., David Charytan, M.D., and Frank Strutz, M.D.

This study was funded by grants from the National Institutes of Health, Deutsche Forschungsgemeinschaft, and support from the Center for Matrix Biology, BIDMC. Ortho Biotech Products, L.P., is the exclusive licensee of BMP-7.

Beth Israel Deaconess Medical Center is a major patient care, teaching and research affiliate of Harvard Medical School, and ranks third in National Institutes of Health funding among independent hospitals nationwide. BIDMC is clinically affiliated with the Joslin Diabetes Center and is a founding member of the Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox.

Very interesting. Bring it on! I’ll volunteer to be a aguinea pig – again!

Hi y’all,

I emailed the author of the letter below, and he gave me permission to repost it here. Interesting stuff. For the record, I am not a believer in the notion that pharma companies withhold promising drugs because they make money off of disease.

Dear Ms Schatell:

I am writing you because your organization would have a vital interest in any discovery that could cure nearly all kidney disease. This potential cure has been around for years but no pharmaceutical company has progressed to human trials as of yet. This potential cure is BMP-7.

        For years clinical studies in animal models have shown the potential for BMP-7 to treat and even regenerate kidneys damaged by progressive kidney disease ( but no drug development company has seriously pushed for human trials.

        Curis ( had the original license for BMP-7 then sold it to Ortho-Biotec ( in 2002.  Ortho-Biotec, who makes over a Billion dollars a year producing an effective drug, Procrit (, commonly used to treat chronic anemia in kidney disease patients, never applied for human clinical trials for BMP-7 and in 2007, dumped the license back to Curis who in turn immediately sold the license to Stryker ( .  Stryker ( already uses BMP-7 in a product, approved by the FDA, which assists in healing bone fractures ( so BMP-7 is safe to use in humans in at least one form but Stryker has yet to apply for human trials to test BMP-7’s use for treating chronic human kidney disease.

        We can’t make Stryker do anything but we can urge Stryker to move forward with applying for a fast track through the FDA to begin human clinical trials or give the license to someone who will.  I have started an ipetition ( for this purpose to be presented to several senior Stryker executives and to the FDA.

        I am asking for your signature on this ipetition and your recommendation to all members of your organization to sign the ipetition. I also ask that you personally contact Stryker to express your entheusiasm, if any, for BMP-7’s rapid development. Otherwise, just your name and public contact email address on the ipetition would be fine.

        All costs to create, maintain and advertise the ipetition are paid out of my own pocket and my time is donated to this project.  My motivation is not all altruistic.  I sit in a dialysis chair for 4 hours, 3 days a week and have seen too many people in the clinics I go to die and too many more suffer much more than I do.
        Your support would be greatly appreciated.

Frank Baker, President
Baker Capital Solutions, LLC
A Factoring Service Company
PMB 192, 3526 Lakeview Pkwy., Suite B
Rowlett, TX 75088
214-668-2886 Voice
972-463-6780 Fax Web Email